Table 4

Summary of step 1 of the stepwise analysis of the ER, PR, and HER2/neu signatures

Rank

MicroRNA

Chromosomal location

Validated mRNA targets

Mean squared error

Median accuracy (%)

ER status

1

miR-342

14q32.2, intronic

-

0.132

84

2

miR-520g

19q13.42, intergenic

-

0.198

73

3

miR-107

10q23.31, intronic

-

0.200

73

4

miR-149

2q37.3, intronic

-

0.201

69

5

miR-520g-h

19q13.42, intergenic

-

0.203

73

6

miR-155

21q21.3, exon

AGTR1, AID, TP53INPI

0.208

70

7

miR-30c

1p34.2, intronic

-

0.210

67

8

miR-382

14q32.31, intergenic

-

0.211

67

PR status

1

miR-520g

19q13.42, intergenic

-

0.180

83.3

2

miR-520d

19q13.42, intergenic

-

0.181

83.3

3

let-7d

9q22.32, intronic

SMC1A

0.185

67

4

miR-328

16q22.1, intronic

CD44, BCRP

0.189

83.3

5

miR-373

19q13.41intergenic

E-Cadherin, lats2 CSDC2, CD44, RAD23B

0.189

83.3

6

miR-217

2p16.1, intergenic

0.196

67

7

miR-504

Xq26.3, intronic

0.198

67

8

miR-485-3p

14q32.31, intergenic

0.201

83.3

HER2/neu status

1

miR-520d

19q13.42, intergenic

0.109

87.5

2

miR-30b

8q24.22intergenic

0.111

83.3

3

miR-217

2p16.1, intergenic

0.114

83.3

4

miR-363

Xq26.2, intergenic

0.115

83.3

5

miR-383

8p22, intronic

0.115

83.3

6

miR-377

14q32.31, intergenic

0.120

87.5

7

miR-130a

11q12.1, intergenic

GAX, HOXA5

0.121

83.3

8

miR-422a

15q22.31, intergenic

0.122

83.3

ER, oestrogen receptor; PR, progesterone receptor; HER2/neu, v-erb-b2 erythroblastic leukaemia viral oncogene homolog 2 receptors.

Lowery et al. Breast Cancer Research 2009 11:R27   doi:10.1186/bcr2257